Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.
Last trade$32.94
Day change-$0.34 (-1.02%)
Day range$32.47 – $33.88
Volume371,065
Market cap$6.89B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$6.89B
Price / earnings
—
Price / book
10.48×
Price / sales
—
EV / sales
—
EV / EBITDA
-11.46×
Profitability
Earnings per share
-$2.46
Return on assets
-66.88%
Return on equity
-77.47%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
7.31×
Quick ratio
7.31×
Cash ratio
6.94×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$395.01M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for IMVT, quarterly periods
Line item
Q2 FY2027 Sep 30, 2026
Q1 FY2027 Jun 30, 2026
Q4 FY2026 Mar 31, 2026
Q3 FY2026 Dec 31, 2025
Q2 FY2026 Sep 30, 2025
Q1 FY2026 Jun 30, 2025
Q4 FY2025 Mar 31, 2025
Q3 FY2025 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$19.14M
$17.69M
$17.27M
$15.44M
$17.51M
$26.02M
$20.17M
$19.78M
Research and development
$85.01M
$142.63M
$142.29M
$98.92M
$114.25M
$101.2M
$93.65M
$94.52M
Total operating expenses
$104.16M
$160.32M
$159.55M
$114.36M
$131.76M
$127.22M
$113.83M
$114.3M
Operating income
-$104.16M
-$160.32M
-$159.55M
-$114.36M
-$131.76M
-$127.22M
-$113.83M
-$114.3M
Interest expense
$6.9M
$7.1M
$0
$0
$5.6M
$6.34M
$0
$0
Income before taxes
-$97.25M
-$153.22M
-$150.7M
-$109.08M
-$125.91M
-$119.7M
-$105.87M
-$110.97M
Income taxes
$0
$0
-$2.84M
$1.55M
$594K
$913K
$583K
$152K
Net income
-$97.25M
-$153.22M
-$147.86M
-$110.64M
-$126.5M
-$120.61M
-$106.45M
-$111.12M
Net income attributable to common shareholders
-$97.25M
-$153.22M
-$147.86M
-$110.64M
-$126.5M
-$120.61M
-$106.45M
-$111.12M
EBITDA
-$104.07M
-$160.23M
-$159.46M
-$114.26M
-$131.66M
-$127.12M
-$113.72M
-$114.2M
Basic earnings per share
-$0.47
-$0.75
-$0.73
-$0.61
-$0.73
-$0.71
-$0.64
-$0.76
Diluted earnings per share
-$0.47
-$0.75
-$0.73
-$0.61
-$0.73
-$0.71
-$0.64
-$0.76
Recent news
Company coverage with links to the original publishers.
Immunovant (IMVT) has gained 24.4% over the past four weeks and Wall Street analysts project a mean price target of $46.61, indicating a potential 30.5% upside from current levels of $35.71. The stock has a Zacks Rank #2 (Buy) rating, supported by positive earnings estimate revisions, though the article cautions that price targets alone should not be the sole basis for investment decisions.
Immunovant, Inc. (IMVT) received an upgrade to Zacks Rank #2 (Buy) based on upward trends in earnings estimates. The company's consensus estimate has increased 1.1% over the past three months. The upgrade positions IMVT in the top 20% of Zacks-covered stocks, suggesting potential near-term stock price appreciation driven by improving earnings outlook.
Immunovant announced it will report financial results for the second fiscal quarter ended September 30, 2026 on November 9, 2026, with a conference call hosted by majority stockholder Roivant Sciences. The company is a clinical-stage immunology firm developing anti-FcRn targeted therapies for autoimmune diseases, with ongoing clinical studies in Graves' disease, myasthenia gravis, and CIDP.
The cutaneous lupus erythematosus (CLE) market is projected to grow at 8% CAGR through 2036, driven by emerging targeted therapies and increased disease awareness. The market was valued at USD 650 million in 2025 across seven major markets. Key pipeline drugs from major pharmaceutical companies targeting plasmacytoid dendritic cells and type I interferon pathways are expected to transform treatment options for CLE patients.
Over 25 pharmaceutical companies are advancing 30+ pipeline drugs for myasthenia gravis treatment, with approximately 5+ therapies in late-stage development. Key players including Immunovant, Cartesian Therapeutics, Novartis, and others are developing promising therapies using novel mechanisms of action such as IgG degraders and complement inhibitors. Recent developments include positive Phase III trial results and regulatory approvals for multiple candidates.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.